Study of BAFF CAR-T cells for CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (BAFF CAR-T cells) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded after at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if these engineered cells can fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CLL or SLL that has returned or not responded after at least 2 prior treatments, including a BTK inhibitor and a BCL2 inhibitor.
- You are 18 years or older.
- You can do your daily activities with little help (ECOG score 0-2).
- Your disease is active (causing symptoms like low blood counts, large spleen or nodes, weight loss, fevers, or night sweats).
- Your heart, lungs, kidneys, and liver are working well enough (specific tests needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
This trial tests a new CAR-T cell therapy (LMY-922) that targets BAFF in people with certain blood cancers that have not responded to standard treatments. The goal is to see if it can shrink or control the cancer.
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
Hear when a new Refractory Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.